BLRXBioLineRx Ltd.

Nasdaq biolinerx.com


$ 1.10 $ 0.01 (0.9 %)    

Thursday, 28-Mar-2024 14:03:56 EDT
QQQ $ 443.93 $ -0.82 (-0.18 %)
DIA $ 397.72 $ 0.20 (0.05 %)
SPY $ 523.07 $ -0.10 (-0.02 %)
TLT $ 94.55 $ -0.08 (-0.08 %)
GLD $ 205.72 $ 2.62 (1.29 %)
$ 1.12
$ 1.11
$ 0.00 x 0
$ 0.00 x 0
$ 1.10 - $ 1.11
$ 0.81 - $ 2.53
163,088
na
81.13M
$ 1.37
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

 bioline-rx-q4-eps-015-beats-022-estimate-sales-480m

BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by...

 earnings-scheduled-for-march-26-2024

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

 earnings-preview-for-bioline-rx
Earnings Preview For BioLine Rx
03/25/2024 15:02:32

 hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

 hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

 earnings-scheduled-for-november-20-2023

Companies Reporting Before The Bell • Greenland Technologies (NASDAQ:GTEC) is projected to report quarterly earnings at $0.05 ...

 bioline-rx-q3-eps-001-may-not-be-comparable-to-021-estimate

BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.21) by...

 bioline-rx-earnings-preview
BioLine Rx Earnings Preview
11/17/2023 14:01:47

 biolinerx-entered-exclusive-license-agreement-to-motixafortide-in-asia-advisored-by-msq-ventures-provides-15m-upfront-and-equity-investment-of-146m-up-to-50m-in-development-and-regulatory-milestones-up-to-200m-in-commercial-milestones

M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX...

 biolinerx-announces-closing-of-exclusive-license-agreement-to-motixafortide-in-asia-and-concurrent-strategic-equity-investment

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in onc...

 biolinerx-touts-encouraging-data-from-therapy-trial-for-first-line-pancreatic-cancer

BioLineRx Ltd (NASDAQ: BLRX) announced data from the single-arm pilot phase of the investigator-initiated CheMo4METPANC Phase 2...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION